Brief: Standard Biotools Announces Sale Of Mass Cytometry Business And Illumina’S Buyout Of Contingent Payments To Advance Merger With Treeline Biosciences
28/07/2026 13:13
BRIEF-Standard Biotools Announces Sale Of Mass Cytometry Business And Illumina’S Buyout Of Contingent Payments To Advance Merger With Treeline Biosciences July 28 (Reuters) - Standard BioTools Inc LAB.O:
STANDARD BIOTOOLS ANNOUNCES SALE OF MASS CYTOMETRY BUSINESS AND ILLUMINA’S BUYOUT OF CONTINGENT PAYMENTS TO ADVANCE MERGER WITH TREELINE BIOSCIENCES
STANDARD BIOTOOLS - TO SELL MASS CYTOMETRY BUSINESS TO MULTIPLEX BIO
STANDARD BIOTOOLS - MASS CYTOMETRY BUSINESS SALE VALUED AT UP TO $10 MILLION
Source text: ID:nGNX8sbBPh
Further company coverage: LAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Standard BioTools
See all newsBrief: Standard Biotools Announces Agreement To Sell Microfluidics Business To Archimed
Brief: Standard Biotools Provides Update On Sale Of Mass Cytometry Business
Standard BioTools Inc. reports results for the quarter ended June 30 - Earnings Summary
Standard BioTools Q2 revenue falls on consumables weakness
Brief: Standard BioTools Q2 EPS USD -0.07